Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Study of a Novel Indibulin Dosing Schedule for the Treatment of Metastatic Breast Cancer

NCT01113970 is registered in ClinicalTrials.gov with Alaunos Therapeutics as lead sponsor.

NCT NCT01113970
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01113970 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Study of a Novel Indibulin Dosing Schedule for the Treatment of Metastatic Breast Cancer
Lead sponsor
Alaunos Therapeutics
Phase
Phase 1
Overall status
Terminated
Start date
April 6, 2010
Completion date
May 21, 2013
Enrollment
35 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic breast cancer